Redwood City, Calif. -- OncoMed Pharmaceuticals, a Redwood City-based biopharmaceutical firm developing antibody therapeutics targeting cancer stem cells, plans to raise up to $115 million in its initial public offering (IPO), the company said in a filing with the Securities and Exchange Commission (SEC). Details of the offering, such as the number of shares to be sold and their expected price range, have yet to be revealed.
The company plans to list its stock on the Nasdaq Global Market under the symbol "OMED."
http://www.oncomed.com/
http://www.sec.gov/Archives/edgar/data/1302573/000119312512227061/d344523ds1.htm
Listings
Notices
Recent Posts
- San Jose-Based Adobe Systems Acquires Behance
- Santa Clara-Based Coherent Acquires Germany's Lumera Laser
- Gangnam Style Becomes First Video to Hit 1 Billion Views on YouTube
- Redwood Shores-Based Oracle to Acquire Eloqua for $871 Million
- Palo Alto-Based Pluribus Networks Raises $23 Million in Third Round
- Foxconn Acquires $200 Million Stake in San Mateo-Based GoPro
- Palo Alto-Based LUMO BodyTech Raises $5 Million in First Round
- Palo Alto-Based Signifyd Lands $2 Million in Seed Funding
- San Francisco-Based FitStar Raises $1M for Health and Fitness Platform
- National Geographic Suspending New Posts on Instagram
Editor: Rich Scherr
For news tips and editorial issues,
contact editor Rich Scherr at
rich@techwiremedia.com
For advertising information, contract
Parul Nath at parul@techwiremedia.com
A Service of Tech Wire Media
Archives
- December 16, 2012 - December 22, 2012
- December 9, 2012 - December 15, 2012
- December 2, 2012 - December 8, 2012
- November 25, 2012 - December 1, 2012
- November 18, 2012 - November 24, 2012
- November 11, 2012 - November 17, 2012
- November 4, 2012 - November 10, 2012
- October 28, 2012 - November 3, 2012
- October 21, 2012 - October 27, 2012
- October 14, 2012 - October 20, 2012
